Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 and Toripalimab in Advanced Solid Tumors
NCT05427396Phase 1Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tifcemalimab in liver cancer, Esophageal Squamous Cell Carcinoma (ESCC), gastric adenocarcinoma and 2 more, sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Incidence of adverse events and serious adverse events at 2 years. Started Jul 2022; status: terminated.
02
Drugs
tifcemalimab
03
Conditions
liver cancerEsophageal Squamous Cell Carcinoma (ESCC)gastric adenocarcinomaCervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05427396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427396.